Industry update: the latest developments in the field of therapeutic delivery, July 2018

    November 2018 in “ Therapeutic Delivery
    Peter Timmins
    Image of study
    TLDR New partnerships, clinical trials, and drug approvals marked progress in therapeutic delivery in July 2018.
    In July 2018, the therapeutic delivery industry experienced various mergers, acquisitions, and partnerships, as well as advancements in clinical trials and FDA approvals. Notable activities included Vicore Pharma acquiring INIM Pharma, Axovant Sciences obtaining gene therapy rights, and Otsuka Pharmaceutical acquiring Visterra. Clinical trials were planned or underway for treatments targeting conditions such as epilepsy, Alzheimer's disease, and HIV. Positive trial results were reported for treatments like Scynexis's ibrexafungerp, Zogenix's fenfluramine, and Cassiopea's clascoterone cream. ViiV Healthcare's two-drug HIV regimen showed effectiveness in maintaining virological suppression, and Janssen reported promising long-term immune response data for an investigational HIV-1 vaccine. KEYTRUDAⓇ demonstrated improved survival in a Phase 3 trial for head and neck cancer, and Pfizer and Lilly's tanezumab showed efficacy in osteoarthritis pain management. The document did not provide specific numbers of participants for the mentioned trials or studies.
    View this study on future-science.com →